Swastham adds governance and strategy leaders to board team

Swastham named Dr. Sunil Deshmukh to the board of its India entity and Rich Brady as strategic board advisor to its U.S. company. The appointments are meant to support the startup’s AI-driven platform for scaling lifestyle medicine globally.

Why it matters: - Swastham is trying to scale an AI-driven lifestyle medicine platform for chronic health needs. - The new appointments add senior experience in governance, finance, strategy and organizational leadership as the company prepares for growth. - Swastham says the platform is designed to help healthcare experts turn proven protocols into personalized digital care at scale.

What happened: - Swastham appointed Dr. Sunil Deshmukh to the Board of Directors of Sucheta Swastham Private Limited in India. - Swastham also named Rich Brady as Strategic Board Advisor to Swastham, Inc. in the U.S. - The company announced the moves on Nov. 11, 2026. - The appointments are intended to strengthen leadership as Swastham develops and expands its AI-powered health platform.

The details: - Dr. Deshmukh has more than 30 years of international leadership experience in business management, corporate strategy, governance and executive development. - He is Co-President of EMCC Asia Pacific, a Global Board Director of the Institute of Management Accountants and Managing Partner of Sunil Deshmukh C-Suite Lab. - Dr. Deshmukh previously served as IMA Global Chair for 2024–25. - His past senior roles include positions at AM International Holdings in Singapore, Indo-Jordan Chemicals, McDonald's India and Foster's India. - Rich Brady is a retired U.S. Marine Corps Colonel, business executive and governance leader. - Brady is CEO of the Society of Defense Financial Management, a global professional association focused on financial excellence across the defense sector. - Brady’s background spans military command, international affairs, corporate governance and financial leadership. - Swastham says the platform combines expert-developed knowledge, governed AI, human oversight and continuous engagement. - The company is initially focused on metabolic and musculoskeletal health, including diabetes, obesity, joint health and muscle health. - Swastham’s longer-term goal is to expand evidence-based lifestyle medicine across geographies and languages.

Between the lines: - The board moves signal that Swastham is prioritizing credibility, disciplined execution and global operating experience as it moves from concept toward scale. - The company is also positioning itself as a bridge between clinical expertise and AI automation, rather than as a fully automated health product. - That approach may matter for trust, especially in healthcare, where governance and human oversight can be as important as technical capability.

What's next: - Swastham says the new leadership support will help as it pursues platform development, strategic partnerships and market expansion. - The company will continue building out its AI-driven programs for expert-led lifestyle care. - Future growth will likely center on scaling the platform while maintaining governance and oversight.